- Home
- CHCO vs KNSA Comparison
CHCO vs KNSA Comparison
Compare CHCO & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHCO
- KNSA
- Stock Information
- Founded
- CHCO 1957
- KNSA 2015
- Country
- CHCO United States
- KNSA United Kingdom
- Employees
- CHCO N/A
- KNSA N/A
- Industry
- CHCO Major Banks
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CHCO Finance
- KNSA Health Care
- Exchange
- CHCO Nasdaq
- KNSA Nasdaq
- Market Cap
- CHCO 1.8B
- KNSA 1.9B
- IPO Year
- CHCO N/A
- KNSA 2018
- Fundamental
- Price
- CHCO $123.11
- KNSA $33.28
- Analyst Decision
- CHCO Hold
- KNSA Strong Buy
- Analyst Count
- CHCO 3
- KNSA 6
- Target Price
- CHCO $132.33
- KNSA $40.83
- AVG Volume (30 Days)
- CHCO 103.5K
- KNSA 711.9K
- Earning Date
- CHCO 07-22-2025
- KNSA 07-29-2025
- Dividend Yield
- CHCO 2.54%
- KNSA N/A
- EPS Growth
- CHCO 6.95
- KNSA N/A
- EPS
- CHCO 8.30
- KNSA 0.07
- Revenue
- CHCO $300,872,000.00
- KNSA $529,332,000.00
- Revenue This Year
- CHCO $9.69
- KNSA $37.21
- Revenue Next Year
- CHCO $1.71
- KNSA $6.10
- P/E Ratio
- CHCO $14.99
- KNSA $504.35
- Revenue Growth
- CHCO 4.61
- KNSA 56.18
- 52 Week Low
- CHCO $102.22
- KNSA $17.82
- 52 Week High
- CHCO $137.28
- KNSA $33.98
- Technical
- Relative Strength Index (RSI)
- CHCO 50.86
- KNSA 65.73
- Support Level
- CHCO $118.72
- KNSA $31.78
- Resistance Level
- CHCO $124.49
- KNSA $33.66
- Average True Range (ATR)
- CHCO 2.59
- KNSA 1.26
- MACD
- CHCO -0.09
- KNSA 0.24
- Stochastic Oscillator
- CHCO 50.63
- KNSA 90.63
About CHCO City Holding Company
City Holding Co is a financial holding company. The company conducts its principal activities through its wholly-owned subsidiary, City National Bank of West Virginia (City National). Through the bank, it provides banking, trust and investment management, and other financial solutions through its network of banking offices located in the states of West Virginia, Virginia, southeastern Ohio, and Kentucky. It offers various products and services such as overdraft facilities, savings accounts, credit cards and debit cards, loans for various purposes, investment advisory, securities brokerage, insurance products, and others. The company's business activities are currently limited to one reportable business segment, which is community banking.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.